4.5 Article

Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells

Journal

JOURNAL OF PROTEOMICS
Volume 76, Issue -, Pages 150-162

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jprot.2012.07.012

Keywords

Mass spectrometry; Proteome profiling; Functional signature; Inflammation; White blood cells; Clinical proteomics

Funding

  1. FWF, der Wissenschaftsfond [L670-B13]
  2. Austrian Christian Doppler Association (Christian Doppler Laboratory for Diagnosis and Regeneration)
  3. Wellcome Trust [WT085949MA]
  4. Austrian Science Fund (FWF) [L 670] Funding Source: researchfish
  5. Austrian Science Fund (FWF) [L670] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

Proteome profiling is the method of choice to identify marker proteins whose expression may be characteristic for certain diseases. The formation of such marker proteins results from disease-related pathophysiologic processes. In healthy individuals, peripheral blood mononuclear cells (PBMCs) circulate in a quiescent cell state monitoring potential immune-relevant events, but have the competence to respond quickly and efficiently in an inflammatory manner to any invasion of potential pathogens. Activation of these cells is most plausibly accompanied by characteristic proteome alterations. Therefore we investigated untreated and inflammatory activated primary human PBMCs by proteome profiling using a 'top down' 2D-PAGE approach in addition to a 'bottom up' LC-MS/MS-based shotgun approach. Furthermore, we purified primary human T-cells and monocytes and activated them separately. Comparative analysis allowed us to characterize a robust proteome signature including NAMPT and PAI2 which indicates the activation of PBMCs. The T-cell specific inflammation signature included IRF-4, GBP1and the previously uncharacterized translation product of GBP5; the corresponding monocyte signature included PDCD5, IL1RN and IL1B. The involvement of inflammatory activated PBMCs in certain diseases as well as the responsiveness of these cells to anti-inflammatory drugs may be evaluated by quantification of these marker proteins. This article is part of a Special Issue entitled: Integrated omics. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available